baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BioMarin Pharmaceutical/ US09061G1013 /

5/15/2024 9:59:42 PM	Chg. -	Volume	Bid10:25:01 PM	Ask9:59:00 AM	Market Capitalization	Dividend Y.	P/E Ratio
80.36USD	-	66,877 Turnover: 3.26 mill.	-Bid Size: -	-Ask Size: -	15.27 bill.USD	-	90.34

GlobeNewswire 5/8 Terns Pharmaceuticals Announces Leadership Changes

GlobeNewswire 11/2/2023 California Life Sciences announces 20th annual Pantheon Award winners

GlobeNewswire 10/2/2023 California’s top scientific innovators selected as finalists for the 20th annual California Life Sci...

GlobeNewswire 3/1/2022 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corpor...

GlobeNewswire 2/14/2022 Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

Newsfile Corp 2/4/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.

GlobeNewswire 1/24/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.

GlobeNewswire 12/23/2021 Lifshitz Law Firm, P.C. Announces Investigations of Amarin Corporation plc (NASDAQGM: AMRN), BioMari...

GlobeNewswire 12/21/2021 BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc....

GlobeNewswire 12/20/2021 BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC

GlobeNewswire 12/20/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...

GlobeNewswire 12/17/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure C...

GlobeNewswire 12/7/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...

GlobeNewswire 12/7/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Befor...

GlobeNewswire 12/1/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...

GlobeNewswire 11/30/2021 AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC

GlobeNewswire 11/28/2021 ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losse...

GlobeNewswire 11/19/2021 AMRN, BMRN & RECAF – Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC

GlobeNewswire 11/15/2021 Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

GlobeNewswire 11/13/2021 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Lo...

GlobeNewswire 11/12/2021 AMRN, BMRN & RECAF – Class Action Alerts: Bronstein, Gewirtz & Grossman, LLC

GlobeNewswire 11/10/2021 INVESTOR REMINDER: BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION DEADLINE- Be...

GlobeNewswire 11/9/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...

GlobeNewswire 11/9/2021 BIOMARIN DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Enco...

GlobeNewswire 11/3/2021 BMRN INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutica...

BioMarin Pharmaceutical/ US09061G1013 /

If you wish to receive reply to your feedback, please provide your email address.